2022
TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).
Tagawa S, Grivas P, Petrylak D, Sternberg C, Swami U, Bhatia A, Pichardo C, Goswami T, Loriot Y. TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2022, 40: tps581-tps581. DOI: 10.1200/jco.2022.40.6_suppl.tps581.Peer-Reviewed Original ResearchMetastatic urothelial cancerBlinded independent central reviewObjective response rateSacituzumab govitecanOverall survivalDay 1Antibody-drug conjugatesCohort 4Eastern Cooperative Oncology Group performance status 0Prophylactic granulocyte colony-stimulating factorActive interstitial lung diseaseAntigen 2 antibodiesClinical benefit ratePerformance status 0Phase 2 doseStudy drug initiationMedian overall survivalProgression-free survivalPhase 2 trialDose-limiting toxicityInterstitial lung diseaseDuration of responseEfficacy/safetyGranulocyte colony-stimulating factorIndependent central review
2019
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
Bardia A, Hurvitz S, DeMichele A, Clark A, Zelnak A, Yardley D, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Caria N, Purkayastha D, Mistry A, Moulder S. Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. Journal Of Clinical Oncology 2019, 37: 1016-1016. DOI: 10.1200/jco.2019.37.15_suppl.1016.Peer-Reviewed Original ResearchEndocrine therapyTriplet therapyMedian PFSClinical benefitCDK4/6 inhibitorsPrimary efficacy end pointSingle-agent endocrine therapyPhase I/IIPhase IMost common AEsShorter median PFSSubsequent-line therapyEfficacy end pointOpen-label trialLines of therapyEfficacy/safetyEntire patient populationCorrelation of biomarkersTumor genomic profileCommon AEsPostmenopausal womenTriplet regimenOptimal regimenWeek 24Investigator assessment
2018
OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy
Hellmann M, Jänne P, Opyrchal M, Hafez N, Raez L, Gabrilovich D, Wang F, Ordentlich P, Brouwer S, Sankoh S, Schmidt E, Meyers M, Ramalingam S. OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. Journal Of Thoracic Oncology 2018, 13: s330. DOI: 10.1016/j.jtho.2018.08.257.Peer-Reviewed Original Research
2017
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
Adams S, Schmid P, Rugo H, Winer E, Loirat D, Awada A, Cescon D, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Card D, Zhao J, Karantza V, Cortes J. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. Journal Of Clinical Oncology 2017, 35: 1008-1008. DOI: 10.1200/jco.2017.35.15_suppl.1008.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerTreatment-related AEsPD-L1 expressionPD-L1Manageable safetyTriple-negative breast cancerECOG PS 0Subset of ptsDisease control ratePhase 2 studyPoor prognostic factorEfficacy/safetyBest overall responseCohort A.Evaluable ptsKEYNOTE-012Median DORMedian PFSPrior chemotherapyData cutoffPembrolizumab monotherapyDurable responsesMetastatic diseasePrior linesPS 0
2000
Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
Khuri F, Glisson B, Meyers M, Herbst R, Thall P, Munden R, Bangert S, Cascino M, Shin D, Kurie J, Papadimitrakopoulou V, Fossella F, Pisters K, Hong W. Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety. Lung Cancer 2000, 29: 63-64. DOI: 10.1016/s0169-5002(00)80205-6.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply